Binding and Cleavage Specificities of Human Argonaute2
Overview
Affiliations
The endonuclease Argonaute2 (Ago2) mediates the degradation of the target mRNA within the RNA-induced silencing complex. We determined the binding and cleavage properties of recombinant human Ago2. Human Ago2 was unable to cleave preformed RNA duplexes and exhibited weaker binding affinity for RNA duplexes compared with the single strand RNA. The enzyme exhibited greater RNase H activity in the presence of Mn2+ compared with Mg2+. Human Ago2 exhibited weaker binding affinities and reduced cleavage activities for antisense RNAs with either a 5'-terminal hydroxyl or abasic nucleotide. Binding kinetics suggest that the 5'-terminal heterocycle base nucleates the interaction between the enzyme and the antisense RNA, and the 5'-phosphate stabilizes the interaction. Mn2+ ameliorated the effects of the 5'-terminal hydroxyl or abasic nucleotide on Ago2 cleavage activity and binding affinity. Nucleotide substitutions at the 3' terminus of the antisense RNA had no effect on human Ago2 cleavage activity, whereas 2'-methoxyethyl substitutions at position 2 reduced binding and cleavage activity and 12-14 reduced the cleavage activity. RNase protection assays indicated that human Ago2 interacts with the first 14 nucleotides at the 5'-pole of the antisense RNA. Human Ago2 preloaded with the antisense RNA exhibited greater binding affinities for longer sense RNAs suggesting that the enzyme interacts with regions in the sense RNA outside the site for antisense hybridization. Finally, transiently expressed human Ago2 immunoprecipitated from HeLa cells contained the double strand RNA-binding protein human immunodeficiency virus, type 1, trans-activating response RNA-binding protein, and deletion mutants of Ago2 showed that trans-activating response RNA-binding protein interacts with the PIWI domain of the enzyme.
Dale R, Mosher R Open Biol. 2024; 14(11):240159.
PMID: 39532148 PMC: 11557233. DOI: 10.1098/rsob.240159.
Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges.
Hofman C, Corey D Cell Chem Biol. 2023; 31(1):125-138.
PMID: 37804835 PMC: 10841528. DOI: 10.1016/j.chembiol.2023.09.005.
Nucleic acid drug vectors for diagnosis and treatment of brain diseases.
Lu Z, Shen J, Yang J, Wang J, Zhao R, Zhang T Signal Transduct Target Ther. 2023; 8(1):39.
PMID: 36650130 PMC: 9844208. DOI: 10.1038/s41392-022-01298-z.
PSMC3 promotes RNAi by maintaining AGO2 stability through USP14.
Jia Y, Zhao J, Yu T, Zhang X, Qi X, Hao T Cell Mol Biol Lett. 2022; 27(1):111.
PMID: 36528617 PMC: 9759854. DOI: 10.1186/s11658-022-00411-y.
Li W, Liu Y, He R, Wang L, Wang Y, Zeng W Nucleic Acids Res. 2022; 50(9):5226-5238.
PMID: 35524569 PMC: 9122594. DOI: 10.1093/nar/gkac315.